Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 2

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Placebo
Drug: Eltrekibart

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 350

Registration Number: NCT06046729

Locations: 🇺🇸
Center For Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸
Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
🇺🇸
Alliance Clinical Research of Tampa, Tampa, Florida, United States

and more 71 locations

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Orforglipron
Drug: Semaglutide

First Posted Date: 2023-09-21

Last Posted Date: 2024-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1576

Registration Number: NCT06045221

Locations: 🇲🇽
Caimed Investigacion En Salud S.A. de C.V., Mexico City, Distrito Federal, Mexico
🇺🇸
Absolute Clinical Research, Phoenix, Arizona, United States
🇺🇸
San Fernando Valley Health Institute, Canoga Park, California, United States

and more 127 locations

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Phase 1

Completed

Conditions: Overweight

Interventions: Drug: LY3437943
Drug: Ethinyl Estradiol
Drug: Drospirenone

First Posted Date: 2023-09-15

Last Posted Date: 2024-07-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 46

Registration Number: NCT06039826

Locations: 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Phase 2

Recruiting

Conditions: Type 2 Diabetes
Obesity

Interventions: Drug: Tirzepatide
Drug: Placebo

First Posted Date: 2023-09-14

Last Posted Date: 2024-08-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 350

Registration Number: NCT06037252

Locations: 🇺🇸
Care Access - Aurora, Aurora, Colorado, United States
🇺🇸
Chase Medical Research, LLC, Waterbury, Connecticut, United States
🇺🇸
Medical Advancement Centers of Arizona, Tempe, Arizona, United States

and more 39 locations

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LOXO-783

First Posted Date: 2023-09-08

Last Posted Date: 2024-07-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 42

Registration Number: NCT06028425

Locations: 🇺🇸
Fortrea Clinical Research Unit, Daytona Beach, Florida, United States

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

Phase 1

Completed

Conditions: Overweight
Obesity

Interventions: Drug: LY3502970
Drug: Placebo

First Posted Date: 2023-09-05

Last Posted Date: 2024-08-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT06023095

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
🇨🇳
Shanghai General Hospital, Shanghai, Songjiang, China

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Orforglipron

First Posted Date: 2023-08-24

Last Posted Date: 2024-10-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 399

Registration Number: NCT06010004

Locations: 🇯🇵
Nakayama Clinic, Nagoya, Aichi, Japan
🇯🇵
Shinkashiwa Clinic, Kashiwa, Chiba, Japan
🇯🇵
Kashiwa City Hospital, Kashiwa, Chiba, Japan

and more 37 locations

A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3876602

First Posted Date: 2023-08-23

Last Posted Date: 2024-07-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 69

Registration Number: NCT06007638

Locations: 🇳🇱
ICON Early Phase Services, LLC, Groningen, Netherlands

A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

Phase 1

Active, not recruiting

Conditions: Dyslipidemias
Non-Alcoholic Fatty Liver Disease

Interventions: Drug: Placebo
Drug: LY3885125

First Posted Date: 2023-08-23

Last Posted Date: 2024-12-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 112

Registration Number: NCT06007651

Locations: 🇺🇸
Worldwide Clinical Trials, Inc., San Antonio, Texas, United States

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3437943
Device: Test
Device: Reference

First Posted Date: 2023-08-22

Last Posted Date: 2024-03-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 57

Registration Number: NCT06003465

Locations: 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
🇺🇸
ICON, Salt Lake City, Utah, United States
🇺🇸
Qps-Mra, Llc, Miami, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy